{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:57:59Z","timestamp":1782943079527,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T00:00:00Z","timestamp":1316131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00520-011-1266-x","type":"journal-article","created":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T20:58:37Z","timestamp":1316120317000},"page":"1729-1735","source":"Crossref","is-referenced-by-count":15,"title":["Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993)"],"prefix":"10.1007","volume":"20","author":[{"given":"Pamela J.","family":"Atherton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli N.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Neben Wittich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminah","family":"Jatoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff A.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,16]]},"reference":[{"key":"1266_CR1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/09553009014550911","volume":"57","author":"JW Hopewell","year":"1990","unstructured":"Hopewell JW (1990) The skin: its structure and response to ionizing radiation. Int J of Radiation Biol 57:751\u2013773","journal-title":"Int J of Radiation Biol"},{"key":"1266_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0360-3016(00)00663-5","volume":"48","author":"KK Fu","year":"2000","unstructured":"Fu KK, Pajak TF, Trotti A et al (2000) A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Rad Oncol Biol Phys 48:7\u201316","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"1266_CR3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/0360-3016(94)00423-I","volume":"31","author":"JO Archambeau","year":"1995","unstructured":"Archambeau JO, Pezner R, Wasserman T (1995) Pathophysiology of irradiated skin and breast. Int J Rad Oncol Biol Phys 31:1171\u20131185","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"1266_CR4","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","volume":"20","author":"RS Herbst","year":"2002","unstructured":"Herbst RS, Maddox A-M, Rothenberg ML et al (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20:3815\u20133825","journal-title":"J Clin Oncol"},{"key":"1266_CR5","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","volume":"290","author":"M Kris","year":"2003","unstructured":"Kris M, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. J Am Med Assoc 290:2149\u20132158","journal-title":"J Am Med Assoc"},{"key":"1266_CR6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201\u20131208","journal-title":"J Clin Oncol"},{"key":"1266_CR7","unstructured":"Cancer Therapy Evaluation Program NCI. Common Terminology Criteria for Adverse events (CTCAE). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm . Accessed 02 August 2010"},{"key":"1266_CR8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","volume":"18","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Maitland ML, Sagaert S et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity group. Support Care Cancer 18:509\u2013522","journal-title":"Support Care Cancer"},{"issue":"4","key":"1266_CR9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/cncr.22444","volume":"109","author":"MM Huschka","year":"2007","unstructured":"Huschka MM, Mandrekar SJ, Schaefer PL et al (2007) A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer 109(4):787\u2013795","journal-title":"Cancer"},{"issue":"2","key":"1266_CR10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02737863","volume":"5","author":"MM Chren","year":"2001","unstructured":"Chren MM, Lasek RJ, Sahay AP et al (2001) Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 5(2):105\u2013110","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"1266_CR11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.currproblcancer.2006.08.003","volume":"30","author":"MM Huschka","year":"2006","unstructured":"Huschka MM, Burger KN (2006) Does QOL provide the same information as toxicity data. Curr Probl Cancer 30(6):244\u2013254","journal-title":"Curr Probl Cancer"},{"key":"1266_CR12","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/annonc\/mdp542","volume":"20","author":"E Basch","year":"2009","unstructured":"Basch E (2009) Patient-reported outcomes in drug safety evaluation. Ann Oncol 20:1905\u20131906","journal-title":"Ann Oncol"},{"issue":"3","key":"1266_CR13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0360-3016(85)90195-6","volume":"11","author":"MB Parliament","year":"1985","unstructured":"Parliament MB, Danjoux CE, Clayton T (1985) Is cancer treatment toxicity accurately reported? Int J Rad Oncol Biol Phys 11(3):603\u2013608","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"1266_CR14","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ijrobp.2010.01.031","volume":"79","author":"RC Miller","year":"2011","unstructured":"Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Stoffel TJ, Haselow RE, Schaefer PL, Bearden JD, Atherton PJ, Loprinzi CL, Martenson JA (2011) Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase 3 double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys 79:1460\u20131466","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1266_CR15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","volume":"113","author":"A Jatoi","year":"2008","unstructured":"Jatoi A, Rowland KM, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the NCCTG (N03CB). Cancer 113:847\u2013853","journal-title":"Cancer"},{"key":"1266_CR16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3816\/SCT.2007.n.015","volume":"4","author":"A Jatoi","year":"2007","unstructured":"Jatoi A (2007) Sunshine and rash: testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash. Support Cancer Therapy 4:198\u2013202","journal-title":"Support Cancer Therapy"},{"key":"1266_CR17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ijrobp.2010.05.065","volume":"81","author":"MA Neben-Wittich","year":"2011","unstructured":"Neben-Wittich MA, Atherton PJ, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Loprinzi CL, Burger KN, Martenson JA, Miller RC (2011) Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys 81:397\u2013402","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1266_CR18","unstructured":"National Cancer Institute, Division of Cancer Control and Population Sciences. Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse events (PRO-CTCAE). http:\/\/outcomes.cancer.gov\/tools\/pro-ctcae_fact_sheet.pdf . Accessed August 2, 2010"},{"issue":"32","key":"1266_CR19","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","volume":"25","author":"A Trotti","year":"2007","unstructured":"Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25(32):5121\u20135127","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-011-1266-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-011-1266-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-011-1266-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:04:11Z","timestamp":1559081051000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-011-1266-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,16]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1007\/s00520-011-1266-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,16]]}}}